• 1
    Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744749.
  • 2
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 13721380.
  • 3
    Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. HEPATOLOGY 1997; 25: 754758.
  • 4
    Lopez-Labrador FX, Ampurdanes S, Forns X, Castells A, Saiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 1997; 27: 959965.
  • 5
    Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996; 88: 742746.
  • 6
    Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. HEPATOLOGY 2006; 44: 10861097.
  • 7
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35S50.
  • 8
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. HEPATOLOGY 2005; 42: 12081236.
  • 9
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421430.
  • 10
    Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. HEPATOLOGY 1995; 21: 28590.
  • 11
    Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737751.
  • 12
    Sorensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with non randomized studies. HEPATOLOGY 2006; 44: 10751082.
  • 13
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995; 122: 161168.
  • 14
    Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695699.
  • 15
    Silini E, Bono F, Cividini A, Cerino A, Maccabruni A, Tirelli C, et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 1995; 22: 691695.
  • 16
    Ansaldi F, Bruzzone B, Salamaso S, Rota MC, Durando P, Gasparini R, et al. Different seroprelavence and molecular epidemiology pattern of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327332.
  • 17
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 10511055.
  • 18
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105114.
  • 19
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 20
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response is associated with improved outcome in patients with HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579587.
  • 21
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 16731680.
  • 22
    Lowy DR, Howley PM. Papilloma viruses. In: KnipeDM, HowleyPM, eds. Fields Virology. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 22312264.
  • 23
    Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D'Amico M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. HEPATOLOGY 1998; 27: 16781686.
  • 24
    Mondelli MU, Cerino A, Lisa A, Brambilla S, Segagni L, Cividini A, et al. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. HEPATOLOGY 1999; 30: 537545.
  • 25
    Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131136.
  • 26
    Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58: 348351.